title: Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to enterobacteria: a multicenter study.
authors.affiliation: Hôpitaux de Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Carbon
authors.forename: C
authors.initials: C
authors.lastname: Auboyer
authors.forename: B
authors.initials: B
authors.lastname: Becq-Giraudon
authors.forename: P
authors.initials: P
authors.lastname: Bertrand
authors.forename: H
authors.initials: H
authors.lastname: Gallais
authors.forename: Y
authors.initials: Y
authors.lastname: Mouton
authors.forename: J P
authors.initials: JP
authors.lastname: Motin
authors.forename: F
authors.initials: F
authors.lastname: Vachon
authors.forename: J M
authors.initials: JM
authors.lastname: Wasmer
authors.forename: A
authors.initials: A
authors.lastname: Buré
mesh_terms: D000583:Amikacin / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004755:Enterobacteriaceae / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000583:Amikacin; D002439:Cefotaxime